SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
57 hedge funds and large institutions have $1.23B invested in SpringWorks Therapeutics in 2019 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 13 closing their positions.
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
81% more capital invested
Capital invested by funds: $681M → $1.23B (+$552M)
40% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 10
30% more funds holding
Funds holding: 44 → 57 (+13)
2.01% more ownership
Funds ownership: 72.34% → 74.35% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.48M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$5.5M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$5.29M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$9.31M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$9.2M |
| 3 |
DM
Deerfield Management
New York
|
-$6.15M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$3.38M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.57M |
SWTX Hedge Fund Activity: Q4 2019 in Review
57 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q4 2019, worth a combined $1.23B — up 81% from $681M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new SWTX positions and 13 closed out — a net gain of 13 holders — while 14 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $12.6M. The largest seller was Millennium Management, cutting an estimated $9.31M.
- 57 institutional investors held SpringWorks Therapeutics (SWTX) as of Q4 2019, up from 44 in Q3 2019.
- Funds reported $1.23B of SpringWorks Therapeutics stock for Q4 2019, up 81% quarter-over-quarter.
- 26 funds opened new SpringWorks Therapeutics positions in Q4 2019 and 13 closed out, a net change of +13 holders.
- The largest SpringWorks Therapeutics buyer in Q4 2019 was BlackRock, an estimated $12.6M added.
- The largest SpringWorks Therapeutics seller in Q4 2019 was Millennium Management, an estimated $9.31M sold.
Based on aggregated 13F filings for Q4 2019.